open
Choose your language
English
English
Home
Products
Specialties
Services
Contact Janssen
Choose your language
English
EN
English
EN
This year on EHA, we shared exciting new data on Imbruvica
®
(ibrutinib) in RESONATE-2
Media Center
Watch professor Ghia reveal how results from up to 7 years of follow-up reinforce the ground-breaking advance in 1L CLL that Imbruvica represents.
[1]
Categories / tags
Imbruvica
Related media
Mode of action Imbruvica
®
+ venetoclax.
This video presents the mode of action of Imbruvica
®
and venetoclax.
Imbruvica
Hematology
Video
Thuis in CLL
Imbruvica
Video
Safety profile
Optimising outcomes for CLL patients treated with IMBRUVICA
®
- Prof. John Gribben
Imbruvica
Video
Efficacy
How IMBRUVICA
®
works
Imbruvica
Video
Imbruvica
®
front line
Prescribing IMBRUVICA
®
front-line
Imbruvica
Video
CLL
Atrial fibrillation and bleeding - Prof John Gribben
Imbruvica
Video
CLL
Long-term survival data in relapsed CLL
Imbruvica
Video
250 000 patients treated with Imbruvica
®
worldwide!
[1]
Imbruvica
Video
What does Prof. John Gribben say about the safety profile of Imbruvica?
About Atrium Fibrillation and bleedings.
Hematologie
Imbruvica
Video
The Bird trial is a Belgian Real-world study
The Bird trial is a Belgian Real-world study where 334 patients with Chronic lymphocytic leukemia, Mantle Cell lymphoma or Waldenstrom Macroglobulinemia are being treated with Ibrutinib.
Imbruvica
Audio
See all related
CP-240988 - June 2021
